Loading
A phase 3 trial of Gemcitabine intravesical system (TAR-200), Mitomycin C and Gemcitabine in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) is a phase 3 interventional study registered as NCT06211764 by Janssen Research & Development, LLC, with 272 participants enrolled, started 2024-04-09 and due to reach its primary completion in 2030-11-27. Interventions recorded: TAR-200, Mitomycin C and Gemcitabine.
Shares Non-muscle-invasive bladder cancer, Johnson & Johnson, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Mitomycin C, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.